Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
European Society for Paediatric Endocrinology, 2024 (ESPE)
Somapacitan is effective and well tolerated in Chinese children with GHD: 52-week results from the randomized phase 3 REAL6 trial
European Society for Paediatric Endocrinology, 2024 (ESPE)
:
Download PDF
